BCL2 and B-cell chronic lymphocytic leukemia: While the next generation of CLL treatments such as the non-covalent BTK inhibitor pirtobrutinib have demonstrated encouraging response rates, its median PFS of 18 months among patients previously treated with both BTK and BCL2 inhibitors indicates that additional treatment options will still be needed for CLL, including allogeneic HCT in appropriate candidates (182).